Doorgaan naar hoofdcontent

Interim analysis of COVID-19 vaccine effectiveness against Severe Acute Respiratory Infection due to SARS-CoV-2 in in...

Interim analysis of COVID-19 vaccine effectiveness against Severe Acute Respiratory Infection due to SARS-CoV-2 in individuals aged 20 years and older
This update reports on one of the ECDC multi-country studies that is centred around the hospital setting and severe disease, with the aim of assessing vaccine effectiveness against severe acuterespiratory infection (SARI) due to laboratory-confirmed SARS-CoV-2 within the ECDC VaccineEffectiveness, Burden and Impact Studies infrastructure (VEBIS) [1,2].
 
Wil je het laatste nieuws in jouw mailbox ontvangen?
Meld je dan aan voor de nieuwsbrief.